0.5186  0.022 (4.43%)		04-22 15:17
Open: 0.4937 High: 0.52 Volume: 232,386		Pre. Close: 0.4966 Low: 0.4602 Market Cap: 8(M)

Short term
Mid term
Targets	6-month :	1.22	1-year :	1.81
Resists	First :	1.05	Second :	1.55
Pivot price	0.62
Supports	First :	0.23	Second :	0.19
MAs	MA(5) :	0.49	MA(20) :	0.53
	MA(100) :	0.71	MA(250) :	1.44
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	14.5	D(3) :	17.7
RSI	RSI(14): 48.2
52-week	High :	2.98	Low :	0.23

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIAF ] has closed above bottom band by 30.7%. Bollinger Bands are 59.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	0.51 - 0.52	0.52 - 0.52
Low:	0.45 - 0.46	0.46 - 0.46
Close:	0.49 - 0.5	0.5 - 0.5

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Thu, 17 Apr 2025
Revolutionary Lung Cancer Detection Test Achieves 92% Accuracy While Slashing Costs by 25% - Stock Titan

Thu, 17 Apr 2025
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - Business Wire

Mon, 07 Apr 2025
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues - Yahoo Finance

Tue, 01 Apr 2025
What's Going On With BioAffinity Shares Tuesday? - bioAffinity Technologies (NASDAQ:BIAF) - Benzinga

Mon, 31 Mar 2025
Record-Breaking 270% Revenue Surge: bioAffinity's Growth Story Takes Unexpected Turn - Stock Titan

Mon, 31 Mar 2025
bioAffinity Technologies, Inc. SEC 10-K Report - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	18 (M)
Shares Float	11 (M)
Held by Insiders	29.1 (%)
Held by Institutions	3.4 (%)
Shares Short	240 (K)
Shares Short P.Month	252 (K)

EPS	-0.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.23
Profit Margin	-90.2 %
Operating Margin	-84 %
Return on Assets (ttm)	-62.4 %
Return on Equity (ttm)	-167 %
Qtrly Rev. Growth	687.4 %
Gross Profit (p.s.)	0.18
Sales Per Share	0.51
EBITDA (p.s.)	-0.43
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.66
PEG Ratio	0
Price to Book value	2.14
Price to Sales	0.95
Price to Cash Flow	-1.24

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.